| pubmed-article:19631529 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19631529 | lifeskim:mentions | umls-concept:C1332822 | lld:lifeskim |
| pubmed-article:19631529 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:19631529 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:19631529 | pubmed:issue | 17 | lld:pubmed |
| pubmed-article:19631529 | pubmed:dateCreated | 2009-8-17 | lld:pubmed |
| pubmed-article:19631529 | pubmed:abstractText | A general way of improving the potency of CXCR3 antagonists with fused hetero-bicyclic cores was identified. Optimization efforts led to the discovery of a series of imidazo-pyrazine derivatives with improved pharmacokinetic properties in addition to increased potency. The efficacy of the lead compound 21 is evaluated in a mouse lung inflammation model. | lld:pubmed |
| pubmed-article:19631529 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19631529 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19631529 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19631529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19631529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19631529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19631529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19631529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19631529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19631529 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19631529 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:19631529 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:PyeS DSD | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:SullivanTimot... | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:MiaoShichangS | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:ChenXiaoqiX | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:GustinDarin... | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:DuXiaohuiX | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:DuquetteJason... | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:WangZhulunZ | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:CollinsTassie... | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:LemonBryanB | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:MedinaJulio... | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:TonnGeorgeG | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:EbsworthKaren... | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:McGeeLawrence... | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:HenneKirkK | lld:pubmed |
| pubmed-article:19631529 | pubmed:author | pubmed-author:SabalanEmmanu... | lld:pubmed |
| pubmed-article:19631529 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19631529 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19631529 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:19631529 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19631529 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19631529 | pubmed:pagination | 5200-4 | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:meshHeading | pubmed-meshheading:19631529... | lld:pubmed |
| pubmed-article:19631529 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19631529 | pubmed:articleTitle | Imidazo-pyrazine derivatives as potent CXCR3 antagonists. | lld:pubmed |
| pubmed-article:19631529 | pubmed:affiliation | Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. xdu@amgen.com | lld:pubmed |
| pubmed-article:19631529 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19631529 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19631529 | lld:pubmed |
